Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and ...

Christiane Eberhardt. Christiane Sigrid Eberhardt is a physician-scientist with a background in vaccine-immunology and is currently working as clinical vaccinologist at the Center ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell ...

Since the Fed's easing cycle began coupled with the outcome of the U.S. election, digital assets have experienced significant ...

Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were presented.

All 20 assets are trading higher. Leaders: RENDER (+13.5%) and ETC (+11.3%). Laggards: BTC (+2.4%) and ETH (+2.6%). The <a ...

Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) SAN DIEGO, Dec. 10, 2024 /PRNewswire/ -- Patients with ...

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.